EUCTR2006-006595-38-GB进行中（未招募）1 期
A Phase II, Open-Label, Single-Arm Study to Assess the Efficacy and Safety of Decapeptyl® SR (3 mg and 11.25 mg formulations) when administered by subcutaneous injection - DISC study
niversity Hospitals Bristol NHS Foundation Trust0 个研究点目标入组 50 人开始时间: 2007年6月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Inclusion Criteria
- •Patients must fulfil all of the following criteria in order to be included in the study:
- •1.The patient has given written (personally signed and dated) informed consent before starting any study-related procedure, which means any assessment or evaluation that would not have formed part of their normal medical care.
- •2.The patient is male and is 18 years of age or older.
- •3.The patient has a histologically or cytologically confirmed diagnosis of prostate cancer and meets the following criteria:
- •Stage T3 or T4, N (any), M (any) with a PSA >5ng/ml or
- •Biochemical relapse following radical prostatectomy or radical radiotherapy for prostate cancer
- •4.Medical castration by means of LHRHa therapy is indicated for the patient.
- •5.The patient has a life expectancy of at least 12 months.
- •6.The patient is able and willing to comply with the requirements of the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.The patient has undergone bilateral orchidectomy.
- •2.The patient is either scheduled to receive, receiving, or is anticipated to require any chemotherapy for prostate cancer, or any other cancer, during the period of his participation in the study.
- •3.The patient is either scheduled to receive, or anticipated to require any surgical intervention for their prostate cancer during the period of his study participation.
- •4.The patient has any condition that in the opinion of the Investigator may preclude the administration of subcutaneous Decapeptyl SR injections.
- •5.The patient has received treatment with any LHRHa, within 1 year prior to study entry.
- •6.The patient has a history of hypersensitivity to Decapeptyl SR or cyproterone acetate (CPA), or to any of the excipients of Decapeptyl SR or CPA.
- •7.The patient has any contraindication to treatment with anti-androgens, including, but not limited to clinically significant abnormalities in liver function.
- •8.The patient has been treated with oestrogens or steroid androgens within the 12 months prior to screening, or is receiving treatment with non-steroid anti-androgens at the time of the Screening visit.
- •9.The patient, in the opinion of the Investigator is at risk of serious complications in the event of tumour flare (e.g. vertebral metastases threatening spinal cord compression, significant obstructive uropathy) on initiation of Decapeptyl SR treatment despite concomitant treatment with anti-androgens.
- •10.The patient has any other condition that, in the opinion of the Investigator, might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study.
- •11.The patient is likely to require treatment during the study with drugs that are not permitted by the study protocol.
- •12.The patient has been treated with any investigational drug or therapy, within the last 30 days prior to study entry.
- •13.The patient has a history of, or known current, problems with alcohol abuse.
- •14.The patient has any mental condition rendering him unable to understand the nature, scope and possible consequences of the study
- •15. The patient has previously been enrolled in the study
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Study to Evaluate the Effectivness and Safety of ADCT-301 in Patients with Relapsed or Refractory Hodgkin LymphomaEUCTR2018-002556-32-FRADC Therapeutics SA100
进行中（未招募）
1 期
A Phase 2 Study to Evaluate the Effectivness and Safety of ADCT-301 in Patients with Relapsed or Refractory Hodgkin LymphomaRelapsed or Refractory Hodgkin LymphomaMedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10020267Term: Hodgkin's disease refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10020234Term: Hodgkin's disease mixed cellularity refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10020233Term: Hodgkin's disease mixed cellularity recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002556-32-DEADC Therapeutics SA100
进行中（未招募）
1 期
A Phase 2 Study to Evaluate the Effectiveness and Safety of ADCT-301 in Patients with Relapsed or Refractory Hodgkin LymphomaEUCTR2018-002556-32-ESADC Therapeutics SA100
进行中（未招募）
1 期
A Phase 2 Study to Evaluate the Effectivness and Safety of ADCT-301 in Patients with Relapsed or Refractory Hodgkin LymphomaEUCTR2018-002556-32-PLADC Therapeutics SA100
进行中（未招募）
1 期
A Phase 2 Study to Evaluate the Effectivness and Safety of ADCT-301 in Patients with Relapsed or Refractory Hodgkin LymphomaRelapsed or Refractory Hodgkin LymphomaMedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10020267Term: Hodgkin's disease refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10020234Term: Hodgkin's disease mixed cellularity refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10020233Term: Hodgkin's disease mixed cellularity recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002556-32-GBADC Therapeutics SA100